Search
Xencor Inc
XNCRAdd to Watchlist
11.220USD
-0.660-5.56%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
831.87MMarket Cap
LossP/E TTM
More Details of Xencor Inc Company
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Xencor Inc Info
Ticker SymbolXNCR
Company nameXencor Inc
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Number of employees250
Security typeOrdinary Share
Fiscal year-endDec 03
Address465 N. Halstead St.
CityPASADENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91107
Phone16263055900
Websitehttps://xencor.com/
Ticker SymbolXNCR
IPO dateDec 03, 2013
CEODahiyat (Bassil I)
Company Executives of Xencor Inc
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Dr. A. Bruce Montgomery, M.D.
Dr. A. Bruce Montgomery, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Kevin C. Gorman, Ph.D.
Dr. Kevin C. Gorman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Ellen Gwen Feigal, M.D.
Dr. Ellen Gwen Feigal, M.D.
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John R. Desjarlais, Ph.D.
Dr. John R. Desjarlais, Ph.D.
Executive Vice President - Research, Chief Scientific Officer
Executive Vice President - Research, Chief Scientific Officer
231.70K
+6.74%
Ms. Celia E. Eckert
Ms. Celia E. Eckert
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
57.51K
+21.17%
Mr. Bart Jan Cornelissen
Mr. Bart Jan Cornelissen
Senior Vice President, Chief Financial Officer
Senior Vice President, Chief Financial Officer
48.35K
-7.24%
Mr. Kurt A. Gustafson
Mr. Kurt A. Gustafson
Independent Director
Independent Director
6.50K
-118.52%
Mr. Richard J. (Rich) Ranieri
Mr. Richard J. (Rich) Ranieri
Independent Director
Independent Director
5.50K
-140.08%
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
President, Chief Executive Officer, Founder and Director
President, Chief Executive Officer, Founder and Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Royalties
80.28M
63.93%
Milestone
45.30M
36.07%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Other
46.52%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.38%
PRIMECAP Management Company
13.94%
BVF Partners L.P.
9.62%
RTW Investments L.P.
9.14%
RA Capital Management, LP
6.39%
Other
46.52%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.03%
Investment Advisor/Hedge Fund
32.00%
Hedge Fund
18.37%
Venture Capital
7.44%
Research Firm
5.09%
Individual Investor
1.17%
Pension Fund
0.85%
Bank and Trust
0.38%
Insurance Company
0.03%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
364
84.79M
119.03%
--
2026Q1
448
94.73M
127.77%
+2.75K
2025Q4
446
84.30M
118.05%
-5.40M
2025Q3
434
80.43M
112.65%
-6.04M
2025Q2
437
81.68M
114.52%
-1.81M
2025Q1
459
80.70M
113.40%
-3.00M
2024Q4
454
76.54M
108.64%
-2.55M
2024Q3
455
73.66M
105.55%
+3.66M
2024Q2
436
65.64M
106.20%
-4.06M
2024Q1
431
66.91M
108.52%
-498.74K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
10.66M
14.54%
+80.73K
+0.76%
Dec 31, 2025
PRIMECAP Management Company
10.22M
13.93%
-456.70K
-4.28%
Dec 31, 2025
BVF Partners L.P.
7.13M
9.73%
+2.51M
+54.43%
Dec 31, 2025
RTW Investments L.P.
6.78M
9.24%
+556.41K
+8.94%
Dec 31, 2025
RA Capital Management, LP
4.74M
6.46%
+4.74M
--
Mar 23, 2026
State Street Investment Management (US)
4.51M
6.15%
+833.42K
+22.69%
Dec 31, 2025
EcoR1 Capital, LLC
3.25M
4.43%
-2.89M
-47.09%
Dec 31, 2025
TCG Crossover Management, LLC
2.45M
3.34%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.09%
Tema Oncology ETF
1.16%
Virtus LifeSci Biotech Clinical Trials ETF
1.06%
Invesco NASDAQ Future Gen 200 ETF
0.97%
Invesco S&P SmallCap Health Care ETF
0.64%
ALPS Medical Breakthroughs ETF
0.43%
State Street SPDR S&P Biotech ETF
0.33%
Inspire Small/Mid Cap ESG ETF
0.3%
Direxion Daily S&P Biotech Bull 3X Shares
0.15%
ProShares Ultra Nasdaq Biotechnology
0.15%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.09%
Tema Oncology ETF
Proportion1.16%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.06%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.97%
Invesco S&P SmallCap Health Care ETF
Proportion0.64%
ALPS Medical Breakthroughs ETF
Proportion0.43%
State Street SPDR S&P Biotech ETF
Proportion0.33%
Inspire Small/Mid Cap ESG ETF
Proportion0.3%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
